Chenggong Tu

Brussels, BRU, Belgium

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

Characterizing the Fate of Anti-CS1 Nanobody Displaying Extracellular Vesicles in Multiple Myeloma.

Characterizing the Fate of Anti-CS1 Nanobody Displaying Extracellular Vesicles in Multiple Myeloma.

Journal: Journal of extracellular vesicles
Published: July 08, 2025

Hypoxia promotes BCMA loss and a suppressive secretome thereby hindering CAR T cell therapy in multiple myeloma.

Hypoxia promotes BCMA loss and a suppressive secretome thereby hindering CAR T cell therapy in multiple myeloma.

Journal: Experimental hematology & oncology
Published: July 04, 2025

The clinically available supplement pyruvate enhances the therapeutic effect of bortezomib in Multiple Myeloma by modulating mitochondrial metabolism.

The clinically available supplement pyruvate enhances the therapeutic effect of bortezomib in Multiple Myeloma by modulating mitochondrial metabolism.

Journal: Cancer letters
Published: June 20, 2025

B7-H3 nanobody-based CAR T cells control multiple myeloma growth, while dual BCMA/B7-H3 CAR T cells overcome antigen escape.

B7-H3 nanobody-based CAR T cells control multiple myeloma growth, while dual BCMA/B7-H3 CAR T cells overcome antigen escape.

Journal: Journal of hematology & oncology
Published: June 03, 2025

Immunopeptidomics identified antigens for mRNA-lipid nanoparticle vaccines with alpha-galactosylceramide in multiple myeloma therapy.

Immunopeptidomics identified antigens for mRNA-lipid nanoparticle vaccines with alpha-galactosylceramide in multiple myeloma therapy.

Journal: Journal for immunotherapy of cancer
Published: April 05, 2025

Syntenin inhibition impairs stroma-tumor communication in multiple myeloma and improves bortezomib treatment efficiency.

Syntenin inhibition impairs stroma-tumor communication in multiple myeloma and improves bortezomib treatment efficiency.

Journal: HemaSphere
Published: February 11, 2025

Hypoxic Bone Marrow Stromal Cells Secrete miR-140-5p and miR-28-3p That Target SPRED1 to Confer Drug Resistance in Multiple Myeloma.

Hypoxic Bone Marrow Stromal Cells Secrete miR-140-5p and miR-28-3p That Target SPRED1 to Confer Drug Resistance in Multiple Myeloma.

Journal: Cancer research
Published: January 19, 2023

Tumour-derived small extracellular vesicles contribute to the tumour progression through reshaping the systemic immune macroenvironment.

Tumour-derived small extracellular vesicles contribute to the tumour progression through reshaping the systemic immune macroenvironment.

Journal: British journal of cancer
Published: March 29, 2022

System Xc- inhibition blocks bone marrow-multiple myeloma exosomal crosstalk, thereby countering bortezomib resistance.

System Xc- inhibition blocks bone marrow-multiple myeloma exosomal crosstalk, thereby countering bortezomib resistance.

Journal: Cancer letters
Published: August 23, 2021

Single-cell analysis at the protein level delineates intracellular signaling dynamic during hematopoiesis.

Single-cell analysis at the protein level delineates intracellular signaling dynamic during hematopoiesis.

Journal: BMC biology
Published: February 05, 2021

In vivo Multi-scale Photoacoustic Imaging Guided Photothermal Therapy of Cervical Cancer based on Customized Laser System and Targeted Nanoparticles.

In vivo Multi-scale Photoacoustic Imaging Guided Photothermal Therapy of Cervical Cancer based on Customized Laser System and Targeted Nanoparticles.

Journal: International journal of nanomedicine
Published: January 12, 2021

High-throughput single-cell analysis of exosome mediated dual drug delivery, in vivo fate and synergistic tumor therapy.

High-throughput single-cell analysis of exosome mediated dual drug delivery, in vivo fate and synergistic tumor therapy.

Journal: Nanoscale
Published: June 24, 2020
Showing 1-12 of 17

Last Updated: 09/26/2026